A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors

Summary

This study is a first-in-human, multicenter, open label, uncontrolled, non-randomized, phase 1a/1b study, to evaluate the safety, tolerability, and preliminary antitumor activity of NB002 in subjects with advanced solid tumors.

Timeline

Start

2023-10

Primary completion

2026-04

Completion

2026-07

Drugs

Indications